Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
IBI-322 by Innovent Biologics for Solid Tumor: Likelihood of Approval
IBI-322 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Data Insights
IBI-322 by Innovent Biologics for Lymphoma: Likelihood of Approval
IBI-322 is under clinical development by Innovent Biologics and currently in Phase I for Lymphoma. According to GlobalData, Phase I...